Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors

被引：0
作者：
Anthony W. Tolcher
Razelle Kurzrock
Vincente Valero
Rene Gonzalez
Rebecca S. Heist
Antoinette R. Tan
Julie Means-Powell
Theresa L. Werner
Carlos Becerra
Chenxi Wang
Cathrine Leonowens
Shanker Kalyana-Sundaram
Joseph F. Kleha
Jennifer Gauvin
Anthony M. D’Amelio
Catherine Ellis
Nageatte Ibrahim
Li Yan
机构：
[1] South Texas Accelerated Research Therapeutics,Division of Hematology and Oncology, Moores Cancer Center
[2] University of California,Division of Cancer Medicine, Department of Breast Medical Oncology
[3] The University of Texas MD Anderson Cancer Center,Division of Medical Oncology, Melanoma Research Clinics
[4] University of Colorado Cancer Center,Division of Medical Oncology, Department of Medicine, Huntsman Cancer Institute
[5] Massachusetts General Hospital,Texas Oncology
[6] Rutgers Cancer Institute of New Jersey,Levine Cancer Institute
[7] Sarah Cannon Research Institute,undefined
[8] University of Utah,undefined
[9] US Oncology-Baylor University Medical Center,undefined
[10] GlaxoSmithKline,undefined
[11] Novartis Pharmaceuticals Corporation,undefined
[12] NEXT Oncology,undefined
[13] Atrium Health,undefined
[14] Cathrine Leonowens Consulting LLC,undefined
[15] Array Biopharma,undefined
[16] Merck & Co,undefined
[17] Brii Biosciences Limited,undefined
[18] Texas Oncology,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 85卷
关键词：
AKT inhibitor; -wild type melanoma; MEK inhibitor; Trametinib; Triple-negative breast cancer; Uprosertib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：673 / 683
页数：10
相关论文
共 153 条
[1]  
Burotto M(2014)The MAPK pathway across different malignancies: a new perspective Cancer 120 3446-3456
[2]  
Chiou VL(2009)PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers Cancer Res 69 4286-4293
[3]  
Lee JM(2017)Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma Cancer 123 2118-2129
[4]  
Kohn EC(2015)Integrated network model provides new insights into castration-resistant prostate cancer Sci Rep 5 17280-910
[5]  
Wee S(2014)Melanoma: molecular pathogenesis and therapeutic management Mol Cell Pharmacol 6 228-920
[6]  
Jagani Z(2015)Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers J Surg Oncol 111 905-1111
[7]  
Xiang KX(2012)Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations Mol Cancer Ther 11 909-255
[8]  
Loo A(2012)Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance Oncotarget 3 1068-748
[9]  
Dorsch M(2012)Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism Cancer Lett 314 244-189
[10]  
Yao YM(2015)Antitumor activity in RAS-driven tumors by blocking AKT and MEK Clin Cancer Res 21 739-114
12345678910